The British pharmaceutical company will begin a global strategic restructuring that will impact mainly on its administrative and commercial areas, although it will preserve its R & D divisions.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The British pharmaceutical company will begin a global strategic restructuring that will mainly impact its administrative and commercial areas, although it will preserve its R&D divisions.
The British pharmaceutical company will begin a global strategic restructuring that will impact mainly on its administrative and commercial areas, although it will preserve its R & D divisions.